SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brawer MK. Screening for prostate cancer. Semin Surg Oncol. 2000; 18: 2936.
  • 2
    Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol. 1999; 162: 293306.
  • 3
    Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1133147.
  • 4
    Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991; 37: 16181625.
  • 5
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51: 222226.
  • 6
    Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274: 12141220.
  • 7
    Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279: 15421547.
  • 8
    Jung K, Stephan C, Lein M, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 1996; 42: 10261033.
  • 9
    Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996; 48: 5561.
  • 10
    Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am. 1997; 24: 353365.
  • 11
    Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol. 1997; 158: 21882192.
  • 12
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer. 1997; 79: 104109.
  • 13
    Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274: 12141220.
  • 14
    Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am. 1993; 20: 665670.
  • 15
    Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270: 860864.
  • 16
    Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000; 56: 255260.
  • 17
    Rodriguez-Patron RR, Mayayo DT, Gonzalez GA, Zuccarino AL, Garcia GR, Cuesta RC. [Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy]. Arch Esp Urol. 2002; 55: 225234.
  • 18
    Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol. 1997; 79(Suppl 1): 6167.
  • 19
    Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147: 815816.
  • 20
    Benson MC, McMahon DJ, Cooner WH, Olsson CA. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol. 1993; 11: 206213.
  • 21
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909916.
  • 22
    Akduman B, Alkibay T, Tuncel A, Bozkirli I. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men. Can J Urol. 2000; 7: 11041109.
  • 23
    Barak M, Cohen M, Mecz Y, et al. The additional value of free prostate specific antigen to the battery of age-dependent prostate-specific antigen, prostate-specific antigen density and velocity. Eur J Clin Chem Clin Biochem. 1997; 35: 475481.
  • 24
    Ciatto S, Bonardi R, Lombardi C, et al. Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting. Int J Biol Markers. 2001; 16: 179182.
  • 25
    Djavan B, Zlotta A, Kratzik C, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999; 54: 517522.
  • 26
    Djavan B, Zlotta AR, Remzi M, et al. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology. 1999; 54: 846552.
  • 27
    Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate. 1998; 37: 133137.
  • 28
    Kikuchi E, Nakashima J, Ishibashi M, et al. Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer. 2000; 89: 842849.
  • 29
    Kuriyama M, Uno H, Watanabe H, Yamanaka H, Saito Y, Shida K. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol. 1999; 29: 617622.
  • 30
    Martinez-Pineiro L, Garcia Mediero JM, Gonzalez GP, et al. Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4–10 ng/ml. World J Urol. 2004; 22: 124131.
  • 31
    Ozdal OL, Aprikian AG, Begin LR, Behlouli H, Tanguay S. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int. 2004; 93: 970974.
  • 32
    Sakai I, Harada K, Hara I, Eto H, Miyake H. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men. Int J Clin Oncol. 2004; 9: 6467.
  • 33
    Baltaci S, Aksoy H, Turkolmez K, Elhan AH, Ozden E, Gogus O. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels. Urol Int. 2003; 70: 3641.
  • 34
    Segawa N, Gohji K, Iwamoto Y, Ueda H, Katsuoka Y. Prostate cancer detection by prostate-specific antigen-related parameters. Hinyokika Kiyo. 2003; 49: 405410.
  • 35
    Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer. 1997; 74: 630636.
  • 36
    Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests—GraphROC for Windows. Scand J Clin Lab Invest. 1995; 222(Suppl): 4360.
  • 37
    Stephan C, Cammann H, Semjonow A, et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem. 2002; 48: 12791287.
  • 38
    Bazinet M, Meshref AW, Trudel C, et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994; 43: 4451.
  • 39
    Rommel FM, Agusta VE, Breslin JA, et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol. 1994; 151: 8893.
  • 40
    Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am. 1993; 20: 653663.
  • 41
    Dincel C, Caskurlu T, Tasci AI, Cek M, Sevin G, Fazlioglu A. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels. Int Urol Nephrol. 1999; 31: 497509.
  • 42
    Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology. 1995; 46: 666671.
  • 43
    Morote J, Raventos CX, Lorente JA, et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml. J Urol. 1997; 158: 502504.
  • 44
    Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol. 2002; 20: 921929.
  • 45
    Finne P, Finne R, Auvinen A, et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology. 2000; 56: 418422.
  • 46
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277: 14521455.
  • 47
    Catalona WJ, Partin AW, Finlay JA, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4.0 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999; 54: 220224.
  • 48
    Jung K, Stephan C, Elgeti U, et al. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen < 4 microg/L: are they useful tools for early detection and screening of prostate cancer? Int J Cancer. 2001; 93: 759765.
  • 49
    Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol. 2002; 168: 922925.
  • 50
    Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng/ml range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. J Urol. 2002; 168: 504508.
  • 51
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the AARAU experience. J Urol. 2001; 166: 851855.
  • 52
    Hammerer P, Graefen M, Henke RP, Haese A, Huland E, Huland H. Ratio free/total PSA (%f-PSA) in men with total PSA 0.5–3.0 ng/ml—Improvement for prostate cancer detection? J Urol. 2000; 163(Suppl): 277A.
  • 53
    Maeda H, Arai Y, Ishitoya S, Okubo K, Aoki Y, Okada T. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol. 1997; 158: 21932196.
  • 54
    Gohji K, Nomi M, Egawa S, et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer. 1997; 79: 19691976.
  • 55
    Lin DW, Gold MH, Ransom S, Ellis WJ, Brawer MK. Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. J Urol. 1998; 160: 7781.
  • 56
    Stephan C, Jung K, Cammann H, et al. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. Int J Cancer. 2002; 99: 466473.